Changing the Pace of the FDA's Standard Review: Part Two

The multi-center, open-label Phase Ib study, ABC-Pax, will assess the safety and efficacy of the regimen in women with triple negative breast cancer.

Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.

Recent survey study of 978 cancer patients and their relatives uncovered reasons behind their willingness, or lack thereof, to participate in clinical research.

The top five episodes of our podcast in the year 2024, highlighted.

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation across multiple demographic groups.